CrossRef Text and Data Mining

Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.

Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results

Yeon Hee Park, Tae Yong Kim, Young-Hyuck Im, Keun-Seok Lee, In Hae Park, Joohyuk Sohn, Soo-Hyeon Lee, Seock-Ah Im, Jee Hyun Kim, Se Hyun Kim, Soo Jung Lee, Su-Jin Koh, Ki Hyeong Lee, Yoon Ji Choi, Eun Kyung Cho, Suee Lee, Seok Yun Kang, Jae Hong Seo, Sung-Bae Kim, Kyung Hae Jung

Cancer Research and Treatment. 2017;49(2):423-429. Published online 2016 August 3 DOI: https://doi.org/10.4143/crt.2016.191

Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results

Cancer Research and Treatment. 2017;49(2):423-429

Link1 Link2

Capecitabine/Bevacizumab Compared to Capecitabine Alone in Pretreated Metastatic Breast Cancer: Results of a Phase III Study)

Kavita Maung, Joyce A. O'Shaughnessy, George W. Sledge

Clinical Breast Cancer. 2003;3(6):375-377

Link1 Link2

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study

J.T. Thigpen

Yearbook of Medicine. 2011;2011:117-118

Link1 Link2

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study

J.T. Thigpen

Yearbook of Oncology. 2011;2011:34-35

Link1 Link2

Treatment with eribulin mesilate could suppress epithelial– mesenchymal transition (EMT) in tumors of patients with metastatic breast cancer – preliminary report of a prospective study

T. Utsumi, T. Hayashi, N. Kobayashi, M. Hikichi, K. Ushimado, Y. Ri, S. Nakano, K. Fujii, T. Ando

European Journal of Cancer. 2017;72:S39

Link1 Link2

Capecitabine/Cyclophosphamide/Methotrexate for Patients with Metastatic Breast Cancer: A Dose-Finding, Feasibility, and Efficacy Study

Gabriella Mariani, Fausto Petrelli, Milvia Zambetti, Angela Moliterni, Angelica Fasolo, Alfonso Marchianó, Pinuccia Valagussa, Luca Gianni

Clinical Breast Cancer. 2006;7(4):321-325

Link1 Link2

Phase III Trials of Eribulin Mesylate (E7389) in Extensively Pretreated Patients With Locally Recurrent or Metastatic Breast Cancer

Chris Twelves, Javier Cortes, Linda T. Vahdat, Jantien Wanders, Corina Akerele, Peter A. Kaufman

Clinical Breast Cancer. 2010;10(2):160-163

Link1 Link2

Evaluation of the willingness-to-pay for cancer treatment in Korean metastatic breast cancer patients: A multicenter, cross-sectional study

Do-Youn OH, Bruce CRAWFORD, Sung-Bae KIM, Hyun-Cheol CHUNG, Jeffrey MCDONALD, Sang Yoon LEE, Su-Kyoung KO, Jungsil RO

Asia-Pacific Journal of Clinical Oncology. 2012;8(3):282-291

Link1

Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin Combined With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive, Early-Stage Breast Cancer

John W. Smith, Svetislava Vukelja, Anthony D. Hoffman, Vicky E. Jones, Kristi McIntyre, Erhan Berrak, James X. Song, Joyce O'Shaughnessy

Clinical Breast Cancer. 2016;16(1):31-37

Link1 Link2

Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate With Trastuzumab as First-Line Therapy for Locally Recurrent or Metastatic HER2-Positive Breast Cancer

Sharon Wilks, Shannon Puhalla, Joyce O'Shaughnessy, Lee Schwartzberg, Erhan Berrak, James Song, David Cox, Linda Vahdat

Clinical Breast Cancer. 2014;14(6):405-412

Link1 Link2

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.